Key result
Intravenous idarucizumab (5 g) promptly reversed the anticoagulant activity of a massive dabigatran overdose, reducing aPTT from 75 to 26 seconds and PT from 26 to 11 seconds.
Why the study?
Does idarucizumab reverse the anticoagulant effect of dabigatran in a massive overdose?
Case Report (n=1)
Does idarucizumab reverse the anticoagulant effect of dabigatran in a massive overdose?
Idarucizumab 5 g IV successfully and rapidly reversed the anticoagulant effect of a massive dabigatran overdose, avoiding the need for emergency hemodialysis.
No takes yet. Share an insight, caveat, or question.
Idarucizumab may aid dabigatran overdose reversal; leaves open need for controlled data on dosing, safety, and outcomes.
Peetermans et al. (2016) conducted a case report in Dabigatran overdose (n=1). Idarucizumab was evaluated on Reversal of anticoagulant activity (aPTT, PT, diluted thrombin time). Intravenous idarucizumab (5 g) promptly reversed the anticoagulant activity of a massive dabigatran overdose, reducing aPTT from 75 to 26 seconds and PT from 26 to 11 seconds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: